FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is a humanized antibody, which, using IGF-I receptor, increases muscle mass, but do not reduce a blood glucose level. This humanized antibody is a humanized antibody against a human IGF-I receptor, its fragment, or its derivative, and it has a specific amino acid sequence. The invention concerns the use of the antibody as part of pharmaceutical compositions for the treatment of diseases, such as muscular atrophy or dwarfism.
EFFECT: obtainment of a humanized antibody against IGF-I receptor.
18 cl, 4 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
